Imalia is conducting in France a second monocentric, prospective, open label pilot study in France of daily dosing of IMA001 in 12 sickle cell disease patients with 3 months of follow-up plus 1 month post dosing.The present study is designed to evaluate, first, the safety and tolerability parameters as well as to measure the plasma and urinary residues of daily oral doses of IMA001. Secondly, the study will evaluate the impact of IMA001 on biological parametersrelated to SCD and on the quality of life of patients.
Imalia to Present Two Abstracts at the 66th American Society of Hematology Annual Meeting
Imalia will present two abstracts at the 66th meeting of the American Society of